Checkpoint Therapeutics’ (CKPT) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report report published on Thursday morning,Benzinga reports. They currently have a $20.00 price target on the stock.

Checkpoint Therapeutics Stock Performance

CKPT stock opened at $3.43 on Thursday. The firm has a 50 day simple moving average of $2.82 and a 200 day simple moving average of $2.35. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97. The stock has a market cap of $154.42 million, a P/E ratio of -1.86 and a beta of 1.23.

Checkpoint Therapeutics (NASDAQ:CKPT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). Sell-side analysts predict that Checkpoint Therapeutics will post -0.81 EPS for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CKPT. Magnus Financial Group LLC raised its position in Checkpoint Therapeutics by 12.9% during the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after acquiring an additional 4,000 shares in the last quarter. Choreo LLC raised its holdings in shares of Checkpoint Therapeutics by 12.2% during the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after purchasing an additional 7,080 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Checkpoint Therapeutics in the 2nd quarter valued at $34,000. Gladstone Institutional Advisory LLC boosted its holdings in Checkpoint Therapeutics by 141.4% in the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company’s stock worth $78,000 after purchasing an additional 20,500 shares in the last quarter. Finally, State Street Corp increased its position in Checkpoint Therapeutics by 32.2% during the third quarter. State Street Corp now owns 94,424 shares of the company’s stock worth $212,000 after buying an additional 23,000 shares during the last quarter. 22.00% of the stock is owned by hedge funds and other institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.